PDS Biotechnology (NASDAQ:PDSB) Trading Down 5.3% – Should You Sell?

PDS Biotechnology Corporation (NASDAQ:PDSB)’s share price dropped 5.3% during mid-day trading on Wednesday . The stock traded as low as $0.90 and last traded at $0.9090. Approximately 659,799 shares were traded during mid-day trading, a decline of 34% from the average daily volume of 999,362 shares. The stock had previously closed at $0.96.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PDSB. Wall Street Zen upgraded shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Tuesday, April 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of PDS Biotechnology in a research note on Wednesday, April 15th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Price Performance

The company has a debt-to-equity ratio of 2.73, a quick ratio of 2.26 and a current ratio of 2.26. The company’s fifty day simple moving average is $1.12 and its two-hundred day simple moving average is $0.90. The stock has a market capitalization of $50.74 million, a PE ratio of -1.36 and a beta of 1.57.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.02. As a group, sell-side analysts predict that PDS Biotechnology Corporation will post -0.52 EPS for the current year.

Institutional Investors Weigh In On PDS Biotechnology

Several hedge funds have recently modified their holdings of the stock. Armistice Capital LLC acquired a new stake in shares of PDS Biotechnology in the fourth quarter worth approximately $2,182,000. Geode Capital Management LLC raised its holdings in PDS Biotechnology by 8.0% in the fourth quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock valued at $401,000 after buying an additional 38,399 shares during the period. Squarepoint Ops LLC raised its holdings in PDS Biotechnology by 116.1% in the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock valued at $295,000 after buying an additional 156,662 shares during the period. Renaissance Technologies LLC raised its holdings in PDS Biotechnology by 25.0% in the first quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after buying an additional 44,100 shares during the period. Finally, Commonwealth Equity Services LLC raised its holdings in PDS Biotechnology by 117.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after buying an additional 106,300 shares during the period. 26.84% of the stock is owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.